Interactive block 2: The drug worked — or did it?: A staged go/no-go case in translational neuropsychopharmacology

Promising preclinical efficacy findings often generate enthusiasm for advancing novel CNS therapeutics. Yet improvements in behavioral performance do not necessarily establish target-specific pharmacology, translational relevance, or an acceptable therapeutic window. How can researchers distinguish a compelling scientific observation from evidence sufficient to justify the next investment in drug development?

This interactive session places participants in the role of a drug development team tasked with evaluating NX-13, a fictional α5-GABA-A receptor negative allosteric modulator being investigated for cognitive impairment in schizophrenia.

Through a staged series of evidence reveals, participants evaluate an initially promising dose-related improvement in rodent recognition memory, followed by pharmacokinetic and blood–brain barrier data, target engagement and receptor selectivity findings, and additional behavioral and safety results that complicate interpretation of the original efficacy signal.

Live audience polling and small-group discussion challenge participants to revisit their go/no-go recommendations as evidence accumulates, distinguish intended pharmacological effects from potential behavioral confounds, and identify the experiments most likely to resolve decision-critical uncertainties.

By integrating neuropsychopharmacology, behavioral neuroscience, translational strategy, and portfolio decision-making, this session explores how to balance scientific promise against mechanistic uncertainty, safety concerns, and limited development resources. Rather than seeking a single correct answer, participants will practice making defensible, evidence-based decisions about when to advance, redirect, or discontinue a CNS drug development program.

The central lesson: A positive experimental result is the beginning of a translational decision, not the end of one.